Patient characteristics: ITT population
| Characteristic . | Treated with ABX-CBL . | Treated with ATG . |
|---|---|---|
| No. patients | 48 | 47 |
| Mean age, y (range) | 38.1 (2-65) | 39.1 (2-65) |
| Male-female ratio, nos. | 31:17 | 27:20 |
| Primary diagnosis, no. (%) | ||
| AML | 14 (29) | 9 (19) |
| ALL | 3 (6) | 8 (17) |
| CML | 7 (15) | 12 (26) |
| Myelodysplastic syndrome | 6 (12) | 4 (8) |
| Lymphoma | 10 (21) | 8 (17) |
| Other | 8 (17) | 6 (13) |
| Risk type, no. (%) | ||
| Good risk | 25 (52) | 22 (47) |
| Poor risk | 23 (48) | 25 (53) |
| Median days from transplantation to randomization, no. (range) | 35.5 (11-100) | 37.0 (14-99) |
| Donor type, no. (%) | ||
| Matched related | 19 (40) | 22 (47) |
| Mismatched related | 1 (2) | 2 (4) |
| Matched unrelated | 21 (44) | 16 (34) |
| Mismatched unrelated | 7 (14) | 7 (15) |
| Preparative therapy, no. (%) | ||
| Chemotherapy with TBI | 29 (60) | 26 (55) |
| Chemotherapy alone | 19 (40) | 21 (45) |
| GVHD prophylaxis, no. (%) | ||
| CSA alone | 5 (10) | 4 (8) |
| CSA + MTX | 10 (21) | 4 (8) |
| CSA + MTX + other | 5 (10) | 5 (10) |
| CSA + other | 9 (19) | 14 (30) |
| FK506 + MTX | 8 (17) | 10 (21) |
| FK506 + MTX + other | 8 (17) | 3 (6) |
| FK506 + other | 3 (6) | 7 (15) |
| GVHD grade, no. (%) | ||
| B/C | 41 (85) | 43 (91) |
| D | 7 (15) | 4 (9) |
| Characteristic . | Treated with ABX-CBL . | Treated with ATG . |
|---|---|---|
| No. patients | 48 | 47 |
| Mean age, y (range) | 38.1 (2-65) | 39.1 (2-65) |
| Male-female ratio, nos. | 31:17 | 27:20 |
| Primary diagnosis, no. (%) | ||
| AML | 14 (29) | 9 (19) |
| ALL | 3 (6) | 8 (17) |
| CML | 7 (15) | 12 (26) |
| Myelodysplastic syndrome | 6 (12) | 4 (8) |
| Lymphoma | 10 (21) | 8 (17) |
| Other | 8 (17) | 6 (13) |
| Risk type, no. (%) | ||
| Good risk | 25 (52) | 22 (47) |
| Poor risk | 23 (48) | 25 (53) |
| Median days from transplantation to randomization, no. (range) | 35.5 (11-100) | 37.0 (14-99) |
| Donor type, no. (%) | ||
| Matched related | 19 (40) | 22 (47) |
| Mismatched related | 1 (2) | 2 (4) |
| Matched unrelated | 21 (44) | 16 (34) |
| Mismatched unrelated | 7 (14) | 7 (15) |
| Preparative therapy, no. (%) | ||
| Chemotherapy with TBI | 29 (60) | 26 (55) |
| Chemotherapy alone | 19 (40) | 21 (45) |
| GVHD prophylaxis, no. (%) | ||
| CSA alone | 5 (10) | 4 (8) |
| CSA + MTX | 10 (21) | 4 (8) |
| CSA + MTX + other | 5 (10) | 5 (10) |
| CSA + other | 9 (19) | 14 (30) |
| FK506 + MTX | 8 (17) | 10 (21) |
| FK506 + MTX + other | 8 (17) | 3 (6) |
| FK506 + other | 3 (6) | 7 (15) |
| GVHD grade, no. (%) | ||
| B/C | 41 (85) | 43 (91) |
| D | 7 (15) | 4 (9) |
There was no significant difference in any characteristic between treatment groups.
ITT indicates intent-to-treat cohort.